Effects of Different Radiation Dosimetry for Anorectal Function of Patients With Pelvic Cancer

Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05832385
Collaborator
(none)
124
36.5

Study Details

Study Description

Brief Summary

In this prospective, open, multicenter, multi-arm, observational controlled study, the investigators investigated the impact of different pelvic radiation doses of anal cancer and rectal cancer patients on the dynamic changes of anal function, and analyzed the correlation between the changes of anal function and the score of anal incontinence in the radiation dose≤50Gy group and >50Gy group. The study population includes 124 patients with anal canal cancer or rectal cancer who have received sphincter preservation treatments (including radiochemotherapy), aged from 18 to 75 years old undergoing sphincter preservation treatments at The Sixth Affiliated Hospital, Sun Yat-sen University and Nanfang Hospital, Southern Medical University. The primary outcome is the average resting pressure of anal sphincter. The secondary outcomes are maximum anal sphincter contraction pressure and Wexner continence score. Evaluations will be carried out at the following stages: baseline (T1), after radiotherapy or chemotherapy (before surgery, T2), after surgery (before closing the temporary stoma, T3), and at follow-up visits (every 3 to 6 months, T4, T5……). Follow-up for each patient will be at least 2 years.

Condition or Disease Intervention/Treatment Phase
  • Radiation: IMRT

Study Design

Study Type:
Observational
Anticipated Enrollment :
124 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Effects of Different Radiation Dosimetry for Anorectal Function of Patients With Pelvic Cancer: a Study Protocol for a Prospective, Observational, Controlled, Multicenter Study
Anticipated Study Start Date :
May 15, 2023
Anticipated Primary Completion Date :
May 30, 2026
Anticipated Study Completion Date :
May 30, 2026

Arms and Interventions

Arm Intervention/Treatment
radiation dose≤50Gy

rectal cancer with IMRT radiation dose≤50Gy

radiation dose>50Gy

anal cancer with IMRT radiation dose>50Gy

Radiation: IMRT
anal cancer: chemoradiotherapy, radiation dose>50Gy; rectal cancer: chemoradiotheray, radiation dose=50Gy
Other Names:
  • chemotherapy
  • Outcome Measures

    Primary Outcome Measures

    1. the average resting pressure of anal sphincter [2023.05-2026.05]

      High-resolution anorectal manometry will be used to assess the average resting pressure and maximal contraction pressure.

    Secondary Outcome Measures

    1. maximum anal sphincter contraction pressure [2023.05-2026.05]

      High-resolution anorectal manometry will be used to assess the average resting pressure and maximal contraction pressure.

    2. Wexner continence score [2023.05-2026.05]

      Wexner continence score 0-20, higher means worse

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion criteria 18-75 years of age. Anal cancer and rectal cancer with pathological diagnosis. Patient will undergo sphincter-preserving therapies. Eastern Cooperative Oncology Group (ECOG) score for performance status is 0-2. Written informed consent. Exclusion criteria Patients who have undergone pelvic surgery, such as rectal cancer surgery and gynaecological procedures. Patients who have received pelvic radiotherapy. Patients with other active malignant tumors. Patients with a history of prior peri-anal abscess, anorectal trauma, and inflammatory bowel disease (IBD).

    Recently (less than 4 weeks) received surgery or patients with recent severe trauma.

    Significant cardiac disease: congestive heart failure of New York Heart Association class ≥2; patients with recent (less than 12 months) active coronary artery disease (unstable angina or myocardial infarction).

    Recent (less than 6 months) thrombosis or embolism events, such as cerebrovascular accident (including transient ischemic attack), pulmonary embolism and deep vein thrombosis.

    Patients with toxicity (Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2) caused by previous treatment that has not subsided.

    Women who suffered anal sphincter tear after vaginal delivery. Pregnant or lactating women.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Sixth Affiliated Hospital, Sun Yat-sen University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hongcheng Lin, vice chief of department of anus and intestine surgery, Sixth Affiliated Hospital, Sun Yat-sen University
    ClinicalTrials.gov Identifier:
    NCT05832385
    Other Study ID Numbers:
    • 2023ZSLYEC-039
    First Posted:
    Apr 27, 2023
    Last Update Posted:
    Apr 27, 2023
    Last Verified:
    Apr 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 27, 2023